SECOV

Germany
|
2020-2025
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • SARS-CoV-2
  • Post COVID-19 condition
  • Blood sample
  • PBMC
  • Serum

Buonsenso

Italy
|
2021-2024
  • General population
  • Infants (<1 year)
  • Adolescents (12-17 years)
  • Children (1-11 years)
  • Hospital
  • SARS-CoV-2
  • Post COVID-19 condition

CAPACoV19

France
|
2020-2022
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • SARS-CoV-2
  • Post COVID-19 condition

BRAINSTORM

France
|
2021-2022
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • SARS-CoV-2
  • Post COVID-19 condition

PoLoCOV-Study

Poland
|
2020-2022
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • SARS-CoV-2
  • Post COVID-19 condition

CISCO-19

United Kingdom
|
2020-2023
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • SARS-CoV-2
  • Post COVID-19 condition

LONGCOVID EXPERIENCE

Spain
|
2023-2024
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • SARS-CoV-2
  • Post COVID-19 condition

CO-Qo-ICU

France
|
2020-2025
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • Intensive care unit
  • SARS-CoV-2
  • Post COVID-19 condition

Balsano

Italy
|
2022-2024
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • SARS-CoV-2
  • Post COVID-19 condition

Cov-N-Psy

Belgium
|
2021-2024
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • SARS-CoV-2
  • Post COVID-19 condition

Yildiz

Türkiye
|
2021-2023
  • Adults (18-64 years)
  • General population
  • Hospital
  • SARS-CoV-2
  • Post COVID-19 condition

COMEBAC 2

France
|
2021-2022
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • SARS-CoV-2
  • Post COVID-19 condition